Investors

Redefining the Treatment of Autoimmune, Infectious and Metabolic Diseases

ImmuPharma PLC (LSE: IMM) is a clinical-stage biopharmaceutical company developing innovative peptide-based therapeutics and precision diagnostics designed to transform the treatment of autoimmune diseases, infectious diseases, and metabolic disorders. Our ambition is clear:

to move beyond symptom control and develop therapies capable of delivering durable remission — and ultimately curative outcomes.

Share Price

A Clear Strategic Vision

The current standard of care in autoimmune disease primarily focuses on controlling inflammation rather than addressing its root cause. ImmuPharma is pioneering a new therapeutic paradigm through its proprietary platforms:

Restoring immune tolerance instead of broad suppression
Identifying and targeting the right patients through companion diagnostics
Expanding peptide innovation into metabolic disease with Kapiglucagon, a novel therapeutic approach targeting key metabolic pathways
Building a precision medicine ecosystem that enables durable remission and improved long-term outcomes

This differentiated strategy positions ImmuPharma at the intersection of immunology, precision medicine, and peptide-based therapeutics, areas driving the next wave of biomedical innovation.

A Differentiated Pipeline with Global Potential

ImmuPharma’s portfolio is built around three complementary pillars: autoimmunity, anti-infectives, and metabolic disease — creating multiple value drivers.

P140 (Lupuzor™): A first-in-class immune normalizer designed to correct underlying immune dysregulation while preserving normal immune function. The platform has potential across multiple autoimmune diseases.
Type M Diagnostic Platform: A next-generation companion diagnostic designed to identify “super-responder” patients across major autoimmune indications, enabling a precision medicine approach and improving clinical outcomes.
Kapiglucagon: A novel peptide-based therapeutic candidate targeting metabolic pathways involved in energy regulation and metabolic diseases, expanding ImmuPharma’s platform into high-growth areas of metabolic medicine.
Anti-infectives (BioAMB & BioCIN): Next-generation therapies designed to address the growing global threat of antimicrobial resistance in severe fungal and bacterial infections.

Together, these programs position ImmuPharma to address major unmet medical needs across multiple high-value therapeutic areas. This diversified pipeline positions ImmuPharma to deliver multiple development and partnering opportunities.

P140

Autoimmunity

Clinic

CDx

Autoimmunity

Clinic

Kapiglucagon

Type 1 Diabetes

Preclinic

BioAMB

Antifungal

Preclinic

BioCIN

Antibiotic

Preclinic

Strategic Partnerships and IP Strength

Robust patent estate.
A scalable peptide-based platform with multiple partnering opportunities across therapeutic areas.

Why Invest in ImmuPharma?

A unique curative vision in autoimmune diseases, moving beyond conventional immunosuppression.
First-in-class therapeutic and diagnostic platforms enabling precision medicine.
Multiple value drivers across autoimmune, infectious, and metabolic diseases.
Clinical assets and near-term development catalysts, including P140 and emerging platform applications.
Strong intellectual property protection and strategic partnerships supporting long-term growth.

Creating Sustainable Value

ImmuPharma is entering a new phase of growth, leveraging its scientific leadership, proprietary peptide platforms, and strategic partnerships to unlock significant value for patients and shareholders.

We’re not just developing new drugs — we’re redefining how autoimmune, infectious, and metabolic diseases can be treated.

Professional advisers

Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
5 St. John’s Lane
London
EC1M 4BH
www.sparkadvisorypartners.com

Joint Broker
Stanford Capital Partners Limited
5-7 Cranwood Street
London
EC1V 9EE
www.stanfordcp.co.uk/contact-us

Joint Broker
Si Capital Limited
46 Bridge St
Godalming
GU7 1HL
info@sicapital.co.uk

Public Relations & Investor Relations
lisa.baderoon@immupharma.com

Principal Bankers
Royal Bank of Scotland plc
62/63 Threadneedle Street
London
EC2R 8LA
www.rbs.co.uk

Auditors
Crowe LLP
55 Ludgate Hill
London
EC4M 7JW
www.crowe.com/uk

Legal Representatives
Broadfield UK
One Bartholomew Close
London
EC1A 7BL
www.broadfield-law.com

Patent Agents
Haseltine Lake Kempner LLP
7th Floor, Cheapside House
138 Cheapside
London
EC2V 6BJ
www.hlk-ip.com

Registrars
Computershare Investor Services PLC
PO Box 82 The Pavilions
Bridgewater Road
Bristol
BS99 7NH
www.computershare.com

Prodrug

What is a Prodrug?

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.